Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives
European Journal of Pharmacology · 2025-11 · 1007 · 178282
DOI: 10.1016/j.ejphar.2025.178282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2025-11. Verfasst von Nathalie Arendt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Cell Biology, Uppsala University, 75124, Uppsala, Sweden. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Antineoplastic Agents, Cardiotoxicity, Intestines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Göran Gustafsson Foundation for the Promotion of Scientific Research, Swedish Research Council, Göran Gustafssons Stiftelser.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced gastrointestinal and cardiac toxicities remain major dose-limiting complications of several cancer treatments, often leading to long-term morbidity and reduced quality of life. Increasing attention has been given to the pleiotropic effects of statins, a class of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors widely used for hyperlipidemia and cardiovascular risk reduction. Beyond their lipid-lowering properties, statins exhibit antioxidant, anti-inflammatory, anti-apoptotic, mitochondrial-protective, and endothelial-supportive activities, making them compelling candidates for repurposing in oncology. This review summarizes the molecular mechanisms through which statins may protect non-target tissues from the collateral damage of chemotherapy. We describe how statins attenuate oxidative stress via NADPH oxidase inhibition and enhancement of endogenous antioxidant defenses, and how they modulate inflammatory responses through suppression of NF-κB signaling and upregulation of endothelial nitric oxide synthase. We further describe their ability to reduce apoptosis by stabilizing mitochondria, activating pro-survival kinases, and dampening inflammasome activity. These effects are supported by preclinical evidence in models of doxorubicin-induced cardiotoxicity and intestinal mucositis. While clinical data remains limited and occasionally inconsistent, the mechanistic rationale and growing experimental data underscore the potential of statins as multi-targeted adjuvant agents to reduce off-target toxicity during chemotherapy. Future clinical studies are warranted to determine statin class-specific effects, optimal dosing, and their full therapeutic potential in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Cell Biology, Uppsala University, 75124, Uppsala, Sweden.
- Department of Pharmaceutical Biosciences, Uppsala University, 75124, Uppsala, Sweden.
- Department of Medical Cell Biology, Uppsala University, 75124, Uppsala, Sweden. Electronic address: femke.heindryckx@mcb.uu.se.
Förderung
- Göran Gustafsson Foundation for the Promotion of Scientific Research
- Swedish Research Council
- Göran Gustafssons Stiftelser
- Swedish Cancer Society
Zitieren
APA
Arendt, N., Kopsida, M., Lennernäs, H., Sjöblom, M., & Heindryckx, F. (2025). Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives. European Journal of Pharmacology, 1007, 178282. https://doi.org/10.1016/j.ejphar.2025.178282
Vancouver
Arendt N, Kopsida M, Lennernäs H, Sjöblom M, Heindryckx F. Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives. European Journal of Pharmacology. 2025;1007:178282. doi:10.1016/j.ejphar.2025.178282
BibTeX
@article{Arendt2025,
author = {Arendt, Nathalie and Kopsida, Maria and Lennernäs, Hans and Sjöblom, Markus and Heindryckx, Femke},
title = {Statin-mediated protection in chemotherapy-induced intestinal and cardiac toxicity: current perspectives},
journal = {European Journal of Pharmacology},
year = {2025},
volume = {1007},
pages = {178282},
doi = {10.1016/j.ejphar.2025.178282}
}
EUVIMED